Concordia Healthcare Corp. and Valeant Pharmaceuticals Intl Inc. Suffer Big Declines

The Democrats have their eyes on limiting drug-price increases. It’s good for patients, but not so much for Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) and Concordia Healthcare Corp. (TSX:CXR)(NASDAQ:CXRX).

The Motley Fool

Hillary Clinton’s tweet reads like this: “Price gouging like this in the specialty drug market is outrageous. Tomorrow I’ll lay out a plan to take it on.”

Clearly, sky-rocketing drug prices is an area of focus for Democratic presidential-hopeful Hillary Clinton. After “outrageous” drug-price increases from companies such as Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) and Turing Pharmaceuticals AG, politicians are taking action and drawing attention to this issue.

Reports state that Valeant’s heart drugs, Nitropress and Isuprel, saw a 212% and 525% price increase after Valeant acquired them, and that one of Turing’s acquired antibiotic drugs was raised to $750 per pill from $13.50 per pill after it was acquired.

Valeant’s stock was down over 16% yesterday as investors react to this. The stock is already very richly valued, and its aggressive acquisition strategy was already under scrutiny, but this tweet and the revelation that U.S. lawmakers are questioning Valeant’s heart drug-price increases seems to be the tipping point.

For its part, Valeant CEO Michael Pearson issued a letter to calm investors. In this letter, he states that Valeant’s exposure to U.S. government reimbursements is lower than any other major pharmaceutical company (about 15% of total revenue) and that Valeant is “well positioned for strong organic growth, even assuming little to no price increases.”

In short, he states that the company’s business model is not dependent on large price increases. He goes on to say that in 2016, 30% of the company’s revenue will be generated from outside the U.S., which has not seen significant price increases, and he continues to expect strong organic growth going forward.

Similarly, Concordia Healthcare Corp. (TSX:CXR)(NASDAQ:CXRX), which also has an aggressive acquisition strategy, whereby it manages and acquires legacy pharmaceutical products and acquires and develops orphan drugs, fell more than 25% yesterday.

This is also no doubt related to the developments in the U.S. political and regulatory scene. And the company just completed an equity offer, where it raised $520 million and issued eight million shares of common stock at $65 to fund the purchase of Amdipharm Mercury Ltd.

Valeant and Concordia have been very successful and profitable, generating strong margins and ROEs, and the stocks’ valuations have more than reflected this fact. Valeant trades at a P/E of 82 times and Concordia trades at a P/E of 90 times, even after the dramatic price declines yesterday.

And this talk from the Democrats clearly casts doubt on the future earnings numbers for these companies, and therefore increases the risk profile of these shares.

Fool contributor Karen Thomas has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »